Thermo Fisher Sells the Picks and Shovels. It's Just Not As Immune to the Gold Rush as You Think.

Somewhere right now a scientist is pipetting a reagent into a 96-well plate, reading the result on a mass spectrometer, ordering a fresh box of tubes, and outsourcing the next clinical trial to a contract research firm. There is a decent chance Thermo Fisher made or sold every one of those things. It did not invent a single drug. It does not own a patent on a blockbuster. It just stands beside every researcher in the world holding the equipment, and gets paid each time science happens. In fiscal 2024 that came to $42.88 billion.¹

The story investors love is clean: Thermo Fisher is the picks-and-shovels play on biopharma. It doesn't gamble on which drug wins; it sells the shovels to everyone digging, so it profits no matter who strikes gold. The metaphor is good. It is also doing more work than the financials can support.

Here is the thesis a smart friend could repeat at dinner: Thermo Fisher is a real picks-and-shovels business, but most of its picks are low-margin, and the mine is more cyclical than anyone selling the metaphor admits. The high-margin instruments everyone pictures are a minority slice. The bulk is distribution and outsourced labor - and when the gold rush cooled after COVID, the shovel merchant's revenue stalled for three straight years.

The shovels everyone pictures are barely a sixth of the business

Say 'Thermo Fisher' to someone in the markets and they picture a gleaming analytical instrument - a mass spectrometer, an electron microscope, the kind of capital equipment with fat margins and a ten-year replacement cycle. That is a real business. It is just not most of the business. In FY2024, Analytical Instruments was 17% of revenue. The single largest segment, at 52%, was Laboratory Products & Biopharma Services - the catalog of tubes, plates, chemicals, and the outsourced clinical-trial machinery the company bolted on later.³ That segment is closer to a distributor and a labor shop than to a high-margin tools maker.

This is why the product/service split matters. Of that $42.88 billion, $25.0 billion came from products and $17.8 billion from services.¹ Selling a microscope is a pick. Running a client's drug trial for them is something else - it's renting out scientists by the hour, a business whose economics look more like consulting than like manufacturing. Thermo Fisher didn't just sell shovels to the gold rush. It started doing the digging too.

How a thermometer company bought its way to every bench

The breadth wasn't organic; it was assembled, deal by deal, and the strategy is legible in the receipts. The modern company was formed in 2006, when Thermo Electron and Fisher Scientific combined in a stock-for-stock merger - roughly $9 billion in combined revenue - to put one company's instruments and another's distribution catalog under a single roof. Regulators noticed the concentration immediately: the FTC made Fisher divest its centrifugal-evaporator line, Genevac, as a condition of clearing the deal.⁴ Even at birth, the company was big enough to trip antitrust.

Then it went hunting for the rest of the bench. In February 2014 it closed the Life Technologies acquisition for roughly $13.6 billion in cash plus assumed debt, buying its way into genomics and life-sciences reagents - the consumables a researcher reorders forever.⁵ And in December 2021, riding a COVID-flush balance sheet, it closed its purchase of PPD for $17.4 billion in cash, adding contract research - the outsourced clinical trials that became the heart of that 52% services-heavy segment.⁶⁷ The pattern is the same each time: don't bet on the drug, own more of the picks, and then own the digging.⁷

Then the gold rush cooled, and the shovel merchant stalled

Here is the part the metaphor papers over. A picks-and-shovels business is supposed to be insulated from the whims of any single prospector - it sells to all of them. But it is not insulated from the rush itself ending. When COVID flooded the world with testing, vaccines, and therapy work, Thermo Fisher's revenue swelled to $44.92 billion in 2022. Then the wave receded. Revenue fell 5% to $42.86 billion in 2023, and sat flat at $42.88 billion in 2024.⁸ Three years, no growth - and not because anyone stopped buying shovels in general, but because a giant temporary mine closed.

Read that sentence carefully, because the company wrote it about itself. The picks-and-shovels seller is admitting, in a federal filing, that it rises and falls with how much its customers feel like spending - and with the macroeconomy of one country. That is the opposite of cycle-immunity. The same proxy set executive performance targets that explicitly baked in the 'anticipated decline in revenue related to COVID-19 testing, vaccines, and therapies.'⁸ The company knew the gold rush was a bubble in its own numbers. The investors reciting the metaphor often didn't.

But isn't a 17% earnings bump in a flat year the whole point?

The fair objection is that this is too harsh. Yes, revenue went sideways - but look at the durability underneath. In a flat-revenue 2024, GAAP diluted EPS still grew 7% to $16.53, and adjusted EPS ticked up too.¹² A genuinely cyclical commodity business collapses in a downturn; Thermo Fisher absorbed the COVID hangover and kept earnings growing. That is exactly what a wide-moat, recurring-revenue arms dealer is supposed to do: the consumables get reordered, the trials run to completion, the installed base of instruments keeps consuming reagents whether or not its customers are flush. The breadth that the acquisitions bought is real, and it dampens the blow.

All true. But notice what the steelman actually concedes: the company's strength is its resilience in a downturn, not its immunity from one. 'We grew earnings while revenue stalled' is the argument for a great defensive business - it is not the argument for a structural toll road that prints money regardless of the cycle. Both things are true at once. Thermo Fisher is an excellent, durable, deeply embedded supplier. It is also more exposed to biopharma's spending mood, and to China, than the picks-and-shovels slogan lets on. The metaphor sells the embeddedness and quietly drops the cyclicality.

So the real read is this: Thermo Fisher didn't get rich by betting on the gold. It got rich by standing beside every prospector with a catalog - and then, with Life Technologies and PPD, by selling them the digging itself. That breadth is a genuine moat, and it keeps earnings growing even when the diggers go quiet. But the slogan smuggles in a promise the filings won't make. The shovel merchant doesn't pick the winner. It still needs the rush. And when the rush is over, even the best-stocked tent on the trail sits flat for three years - and says so, in its own words, to the SEC.